State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in CytomX Therapeutics Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 9,025,855 shares of CytomX Therapeutics Inc common stock.
  • Percent of class: The reported position represents 4.1% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared voting power over 8,753,246 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 9,025,855 shares, with sole dispositive power of 0.
  • Subsidiaries involved: Five subsidiaries are identified as having acquired the securities, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, each classified as an investment adviser.
  • Triggering date: The event requiring the filing occurred on September 30, 2026, according to the statement.

State Street Corporation's Schedule 13G Filing on CytomX Therapeutics

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership in CytomX Therapeutics Inc (CUSIP 23284F105). According to the filing, the triggering event date was September 30, 2026, and the statement was signed on November 9, 2026 by Alok Maheshwary, Senior Vice President. The filing was submitted on November 10, 2026.

The filing reports aggregate beneficial ownership of 9,025,855 shares of CytomX Therapeutics common stock, representing 4.1% of the class. State Street disclosed zero sole voting power and zero sole dispositive power over these shares. Shared voting power was reported at 8,753,246 shares, while shared dispositive power covered the full 9,025,855 shares, according to the statement.

As a parent holding company, State Street identified five subsidiaries through which the securities were acquired: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. All five are classified as investment advisers (IA) in the filing. Item 5 of the filing notes ownership of 5 percent or less of the class. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 4.1% beneficial ownership stake, totaling 9,025,855 shares, in CytomX Therapeutics Inc common stock as of September 30, 2026, held through five investment adviser subsidiaries with no sole voting or dispositive power reported.